3D MEDICINES INC.

Other languages 3D Medicines Inc.

Equities

1244

KYG8872R1011

Market Closed - Hong Kong S.E. Other stock markets 01:38:17 17/05/2024 pm IST			5-day change	1st Jan Change
7.51 ^HKD	+4.02%		+11.26%	-1.70%

29/03	3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12%	MT
28/03	3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12%	29/03
3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Simcere Pharmaceutical’s Profit to Fall Up to 27% in 2023	19/02
Simcere Pharmaceutical Expects Up to 26% Fall in 2023 Profit; Shares Slide 3%	19/02
3D Medicines Inc. commences an Equity Buyback Plan for 25,605,700 shares, representing 10% of its issued share capital, under the authorization approved on June 26, 2023.	31/01
Alphamab Oncology and 3Dmedicines Enters into A Licensing Agreement with Glenmark for KN035	25/01
Alphamab Oncology Unit, 3D Medicines Grants Glenmark Unit License to Commercialize Sarcoma Injectable	25/01
3D Medicines Unit Receives Repayment for 60 Million Yuan Loan	22/01
3D Medicines Inc. Receives Approval from Fda to Proceed with Aglobal Phase Iii Trial for Treatment of the First Line Mismatch Repair ProficientAdvanced or Recurrent Endometrial Cancer	30/23/30
Sellas Life Sciences Expects to Complete Patient Enrollment for Phase 3 REGAL Trial in November	13/23/13
3D Medicines Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	25/23/25
3D Medicines Expects Higher H1 Earnings	10/23/10
3D Medicines Inc. Provides Earning Guidance for the Six Months Ended June 30, 2023	07/23/07
3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/23/30
3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/23/30
Voluntary Announcement A Phase II Study Protocol of Envafolimab for the Treatment of Dmmr Advanced Solid Tumors Has Been Allowed to Proceed by U.S. Food and Drug Administration by 3D Medicines Inc	30/22/30
Fed Rate Hike Snap Two-Day Gains of Hong Kong Stocks; 3 Companies Debut on the Hong Kong Stock Exchange	15/22/15
3D Medicines Inc. has completed an IPO in the amount of HKD 408.423 million.	14/22/14
3D Medicines Inc. has filed an IPO in the amount of HKD 429.023996 million.	29/22/29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Rankings

More Top / Flop

Rankings

More Top / Flop

Currency / Forex

Commodities

Cryptocurrencies

Cryptocurrencies

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW